How Recent Technology Transformations in Pharma Analytics Impact...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

How Recent Technology Transformations in Pharma Analytics Impact Business

Silji Abraham, Chief Digital and Transformation Officer, West Pharmaceutical [NYSE:WST]

Silji Abraham, Chief Digital and Transformation Officer, West Pharmaceutical [NYSE:WST]

Analytics has a long history of existence in different forms and practice. From the beginning, people predicted things about the future—predicting rain for the afternoon based on seeing clouds in the sky was perhaps one of the earliest forms of predicting. While computing and digitally capturing of data occurred later in history, we can easily assume that human brains were doing analytics and decision-making in everyday living throughout the history of mankind. The question has always been how much and how accurately into the future one can predict.

Analytics has the capability to not just tell us what is happening, but more importantly, why it is happening and whether it is likely to happen again. We can certainly agree that analytics is a phenomenon at scale today, which is applied in every aspect of life and business with the ability to digitize data and the democratization of computing. Almost all business decisions being made today are driven by some underlying analytics so that individuals can make decisions and hypotheses based on data rather than just human intuition. When you can truly rely on data that requires less human involvement, the analytics are highly predictable and reliable.

The fusion of computation and biology is indeed the new frontier of analytics/machine learning and is being pursued by almost all cutting-edge research in life science and healthcare. Today, we have the ability to digitize human genome at scale. Think about the possibility of looking into more than 3 billion base pairs of genetic codes of millions/billions of people! It is certainly an exciting possibility for analytics/machine learning and discovery. We are at the beginnings of personalized care in the world of healthcare by simply being able to unravel the mystery of the genetic codes, which dictate every aspect and characteristic of each of us and, until recently, have been an unknowable mystery of nature. The market is witnessing many instances of joining hands between tech companies and life science/Pharma companies to pursue the fusion of biology and computing.

Molecular biology is a science focused on learning the complexities of nature and cell using computing, and analytics has helped tremendously on this journey.

The future for life science and healthcare is indeed very fascinating and promising with the fusion of computing at scale, machine learning/artificial intelligence with algorithmic maturity, and techniques and opportunity to digitize molecular biology and proteomics. We will continue to see transformational progress in the coming decades, especially in the following three areas in life science and healthcare:

1. Generative chemistry powered by artificial intelligence/ machine learning will enable finding molecules with certain potential therapeutic characteristics to cure or treat more diseases.

The fusion of computation and biology is indeed the new frontier of analytics/ machine learning and is being pursued by almost all cutting-edge research in life science and healthcare

2. Ability to perfect the manufacturing and delivery of the evolving cell and gene therapy with digitization of molecular biology and proteomics.

3. A world of connected humans with biosensors with non-intrusive form factors that continuously read vitals or life sustaining functions abstracted as signals and do edge computing and analytics to predict what is required to maintain good health, just like preventive maintenance for machines.

While we may never be able to unlock all the secrets of nature, we are indeed gearing up for an era with the potential ability to fight the worst diseases of nature, which too often lead to premature death for too many.

Weekly Brief

Read Also

Late Pack Customization: the Way to Optimize Pharma Supply Chain

Late Pack Customization: the Way to Optimize Pharma Supply Chain

Tomasz Nawrocki, Pharmaceutical Supply Chain Service Department Director/ CEO Synoptis Industrial, Grupa NEUCA
What the New EMA Draft

What the New EMA Draft "Guideline on Computerized Systems and Electronic Data" Means to Your Systems

Cathlin Shapiro, Parexel, Director, Technology Quality Assurance
How Contract Research Organisations Can Help the Pharma Companies

How Contract Research Organisations Can Help the Pharma Companies

Skye Fitzgerald, Data Analytics Manager, Jazz Pharmaceuticals
Why are Contract Research Organizations Significant in the Pharma Industry?

Why are Contract Research Organizations Significant in the Pharma Industry?

Willie Martin, Director, Discovery Process, Alkermes
How can Manufacturing Companies Keep Pace with the Shifting Trends of Oncology Drug Development

How can Manufacturing Companies Keep Pace with the Shifting Trends of Oncology Drug Development

Stewart Campbell, VP & General Manager at West Pharmaceutical & Li Chen, VP & General Manager at West Pharmaceutical
Optimizing Alkermes' R&D Model for Success

Optimizing Alkermes' R&D Model for Success

Craig Hopkinson, M.D., CMO and Executive Vice President, Research and Development, Alkermes